Consistent with these findings, a direct MALAT1–EZH2 interaction has been implicated in renal cell carcinoma metastasis, as well as in osteosarcoma, as outlined in a recent study that directly linked the metastasis-promoting MALAT1–EZH2 interaction to E-cadherin epigenetic repression in this tumour type and established MALAT1 as a predictive biomarker of poor survival in osteosarcoma patients [77]. Here, EZH2 is linked to neoplasm.